XW Laboratories Inc., a Wuhan, China-based biopharmaceutical Research and Development (R&D) company focused on neurological disorders, closed a $17.5m Series B financing.
The round was led by Elements Capital and WI Harper with participation from new investor KTB Network, and all existing investors Kleiner Perkins Caufield & Byers China (KPCB China), Johnson & Johnson Innovation – JJDC, Inc. and WuXi Venture.
The company will utilize the funds to continue the development of its multiple programs that are entering clinical and IND-enabling studies.
Led by Dr. Jia-Ning Xiang, Founder and CEO, XW Laboratories is a biopharmaceutical company focused on the development of a portfolio of novel compounds for the treatment of neurological disorders with primary research and development activities. Located in Wuhan, China and New Taipei City, Taiwan. XW Labs employs a platform-centric pipeline and has expertise in medicinal chemistry for enhanced drug design.
The company is built upon three platforms, all of which have the potential to host multiple programs for a broad number of indications. XW Labs’ first two platforms improve the pharmacokinetics and safety profiles of existing drugs for best-in-class medicine and potential new indications. Its third platform is a novel platform focused on reducing damage to the mitochondria, which has been linked to many neurological disorders.